Fifteen Klebsiella pneumoniae clinical isolates showing non-susceptibility to carbapenems and resistant to colistin were collected in an Italian hospital. All isolates resulted negative to AmpC, MBL and ESBL production but positive to modified Hodge test, therefore were evaluated as KPC producers. The presence ofblaKPC genes was verified by polymerase chain reaction (PCR) and sequencing. Furthermore, molecular typing was performed by multilocus sequence typing (MLST). PCR analysis and nucleotide sequencing revealed that all 15 isolates carried the blaKPC-3 gene. MLST analysis attributed the isolates from all patients to belong to the sequence type ST512. All isolates showed extensively drug-resistant (XDR) phenotype. The emergence of colistin-resistant K. pneumoniae underscores the implementation of strict control measures to prevent the dissemination of these organisms in hospitals.
In recent years the emergence of Klebsiella pneumoniae isolates producing KPC carbapenemases is rapidly spreading worldwide and the problem in clinical settings is increasing. First KPC isolate was reported in 2001 from North Carolina and have now been reported in 37 states in the United States. The first outbreak of KPC-producing K. pneumoniae outside of the USA was in Israel. KPC have been reported in many countries including: China, Brazil, France, Greece, England, Sweden, Belgium, Germany, Korea, India, Italy, Denmark, Finland, Switzerland, Spain, Columbia, Argentina, Norway and Israel (l). KPC are capable of hydrolyzing a broad spectrum of beta-lactams including penicillins, cephalosporins, carbapenems and monobactams. The detection of carbapenemase producers in clinical specimens is based firstly on a careful analysis of susceptibilitytesting results obtained with automated systems, liquid media, and disk diffusion tests. Automated systems may not reliably detect all types of carbapenemase producers, and discrepancies may arise (2) . A series of non-molecular-based tests have been recommended for the screening detection of carbapenemase activity: the modified Hodge test and carbapenemase inhibitor test. Inappropriate treatment may be the consequence of inaccurate detection of KPCs by routine susceptibility screening helping its dissemination and becoming an increasingly significant problem because of the high mortality rate and limited therapeutic options (2) (3) (4) . KPCs are encoded by the gene bla KPc ' that has great potential for inter-species and geographic dissemination due to its location within a transposon, a genetic element which is capable of insertion into diverse plasmids of Gram-negative bacteria. To date, 11 different variants (KPCl/2-KPCI2) of the KPC enzyme have been identified, with KPC-2 and KPC-3 reported the most frequently. An examination of all KPC isolates between the years 1996-2008 from 18 states, as well as Israel and India, revealed that multilocus sequence type 258 (ST258) is the single dominant strain that actually is considered as the international epidemic clone. In late 2005, a highly epidemic clone, genetically related to KPC-3 ST258, spread in Israel; molecular epidemiological studies on isolates from several hospitals in Israel, in subsequent years, identified the outbreak strain as a KPC-3 ST512 clone that had only a single mutation compared to ST258 (5) (6) (7) .
Most KPC infections are susceptible only to gentamicin, polymixins and tigecyline (3, (8) (9) and, of these, colistin is often the only agents active against KPC bacteria (10, II) and is frequently used for the treatment of the respective infections. However, in the past few years resistance to these compounds has begun to emerge: cases of KPC colistin-resistant have been reported from various parts of the world, e.g. Greece (12, 13) , Israel (14) , South Korea (15), United States (16) and recently also in Italy (17) . The multiresistent K. pneumoniae strains have been generally attributed to the international epidemic clone ST258 (18, 19) .
In this report we present the phenotypic and molecular characterization of KPC-producing carbapenem-and colistin-resistant K. pneumoniae clinical isolates in an Italian hospital.
MATERIALS AND METHODS

Bacterial identification and antimicrobial susceptibility
From January to June 2012, isolates ofK. pneumoniae resistant to the carbapenems and colistin were collected from clinical specimens. The study included fifteen isolates obtained from the following samples: wound swab (n=3), skin swab (n=l), urine (n=5), sputum (n=3) bronchoalveolar lavage (BAL; n= 1) blood (n= 1) and pharyngeal swab (n= 1). The demographic and clinical features of the 15 patients are shown in Table I .
Bacterial identification and drug susceptibility of all isolates were tested using the Vitek 2 automated system (biolvlerieux, France). Escherichia coli ATCC 25922 was used as quality control strain. Susceptibility for colistin was also confirmed using the E-test (biolvlerieux) according to the manufacturer's instructions and interpreted using the EUCAST cut-off (http://www.eucast.org).Imipenem resistance was defined as an MIC of2:8 ug/rnl, and colistin resistance was defined as an MIC of2:2 ug/rnl. Phenotypic screening for carbapenemases was carried out on all isolates by using the modified Hodge test using disks of meropenem 10 ug and ertapenem 10 ug according to the manufacturer's instructions. All isolates were positive for carbapenemase production by Modified Hodge test.
For the identification of strains, MBL was tested using E-tests IP/IPI (lmipenem/ Imipenem +ethylene diaminetetraacetic acid (EDTA).The absence ofa "phantom" zone and ofthe ratio IP/IPI <8 confirmed the absence ofMBL in the samples tested. In addition, the extended spectrum B-lactamase (AmpC) production was tested on Mueller-Hinton agar (biolvlerieux, France) by the E-test (Liofilchem) CN/CNI (CefotetaniCefotetan + Cloxacillin). In our samples the ratio ofCN/CNI <8 and the absence ofa "phantom" zone was interpreted as non-producing AmpC. Moreover, for the detection of ESBL production a disk of cefotaxime 30 ug, aztreonam 30 ug, ceftazidime 30 ug, amoxicillinlclavulanate 30 ug and ceftriaxone/cefoxitin 30 ug was used. In accordance with the manufacturer's instructions, the absence of an ESBL, based on the synergy between clavulanic acid and one or several antibiotic molecules, was determined in all the samples.
Molecular typing
KPC-type B-lactamasegene was identifiedby polymerase chain reaction and sequencing. A couple of specific primers for blaKPC gene of K. pneumoniae was designed, KPC forward GCCTTCATGCGCTCTATCGG and KPC reverse AGCCTTACTGCCCGTTGACG, from the reference sequence submitted in GenBank (AF297554.l) using Primer-Blast software. The nucleotide sequence for KPC-2 differed from KPC-l by a single nucleotide at position 650 (A-G), and the sequence for KPC-3 differed from KPC-2 by a single nucleotide at position 944 (C-T). The amplicon was designed so that the genes for isoenzymes KPC-l, -2, and -3 could be easily distinguished by sequencing reaction. The PCR was performed in a total reaction mixture volume of 50 ul consisting of 5 ul of lOX PCR Buffer II (500 mmol I-I KCI, 100 mmol l' Tris-HCI, pH 8.3; Applied Biosystems, Foster City, CA, USA), 1.5 mmol I-I MgCI2, 200 umol I-I of each dNTP (Roche Diagnostics, Basel, Switzerland), 2.5 IV AmpliTaq Gold Polymerase (Applied Biosystems), 10 pmol of each primer, I ul (lOng) of DNA template and ultra pure water to volume. The PCR was carried out on a GeneAmp® PCR System 9700 (Applied Biosystems), using the following conditions: initial denaturation at 95°C for 10 min; 40 cycles of denaturation (94°C for 30 s), annealing (56°C for 30 s) and extension (72°C for I min); and a final extension step at noc for 10 min. Samples were stored at 4°C prior to analysis.
The PCR products were analysed by gel electrophoresis through 2% agarose in 1 . TAE buffer, and visualised by UV transillumination after staining with ethidium bromide. The PCR products with the predicted sizes of 441 bp were obtained from all strains and no amplification was obtained in the negative control. The PCR products were purified and sequenced using BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems) as recommended by the manufacturer. The sequences were determined with an ABI Prism 3130XL Genetic Analyser (Applied Biosystems). Results were compared and aligned with reference sequences using the online BLAST database and Seqscape software (Applied Biosystems). Clonality of the K. pneumoniae isolates was investigated by multilocus sequence typing (MLST), that requires the molecular typing of 7 housekeeping genes as described by Diancort at al. (20) . We performed this assay following the simplified protocol, which uses primers with universal sequencing tails, which allows to amplify all genes by PCR at the same temperature and to sequence all genes with the same forward and reverse sequencing primers. Sequence types were determined using the K. pneumoniae MLST database, 2011 (21) .
RESULTS
Antibiotic susceptibility by Vitek 2 showed that the strains were all resistant to carbapenems (imipenem and meropenem), cephalosporins, and penicillins (Table II) . For colistin, the MICs ranged between 8 and 16 ug/ml and the isolates were characterised as resistant. For tigecycline, the MIC often isolates was 2 ug/rnl and one 4 ug/ml; MICs of the remaining four ranged from 0.5 ug/ml to 1 ug/rnl and were considered to be susceptible to this drug. Resistance to aminoglycosides varied; all strains were resistant to amikacin, while for gentamycin the MIC of eleven isolates was 4 ug/ml and one~16 ug/ml, the MIC of the remaining three was~2llglml and were considered to be susceptible to this drug (Table II) .
All our isolates resulted negative to AmpC, MBL and ESBL production but positive to modified Hodge test, therefore were evaluated as KPC producers.
PCR analysis and nucleotide sequencing revealed that all 15 isolates carried the blaKPC-3 gene. MLST analysis attributed the isolates from all patients as belonging to the sequence type ST512 (Table I) .
DISCUSSION
KPC-producing K. pneumoniae has become a major clinical pathogen. Colistin, which had been in disuse for decades due to concerns about toxicity and availability of safer antimicrobial agents, now represents one of the few remaining antibiotics available for treatment of infection caused by multi-drug-resistant Gram-negative bacteria. The increasing use of this antimicrobial agent has developed the emergence of colistin resistance (18) . The spread of colistin-resistant K. pneumoniae strains was reported in 2011 in Italian hospitals (19) . In this report, a total of 81 KPC-producing K. pneumoniae strains were isolated between January and June 2012, of which, 15 (18.5%) were also resistant to colistin. Patients colonised with colistinresistant KPC producers could be an important source for further propagation of these pathogens, especially in immunocompromised patients in whom the emergence of multi-drug resistant organisms (MDR) and antifungal drug resistance have been increasingly recognized as a major cause of morbidity and mortality (10, 22) .
In this paper, we report fifteen isolates showing extreme drug-resistant (XDR) phenotype, defined as resistance to all but one or two antibiotic classes. For these reasons, most authors recommend using combination therapy with different classes of antibiotics to improve the efficacy and to prevent the emergence of further resistance (23) .
Phenotypic confirmatory testing for KPCproducing bacteria has proved useful for verifying the presence of a KPC of the clinical isolates. The difficulty of identifying KPC-mediated carbapenem resistance using routine method laboratory identification highlights the need for accurate screening methods for these enzymes to limit the spread of this resistance mechanism. In recent years, the spread of KPC-producing bacteria created the necessity to implement the laboratory with tests able to promptly report any carbapenem-resistant isolate to either the clinician for the appropriated antimicrobial therapy or the hospital infection control team for the appropriate contact isolation precautions.
The detection of carbapenem-resistant organisms may be problematic because some isolates express low levels of resistance that may not be detected by conventional methods. The presence of ESBLs and AmpC can mask the expression of KPc. Our study shows how the phenotypic methods excluding the presence of these enzymes in the samples tested confirms that our strains are producers of KPC. To date, 11 different KPC variants (KPC 112-KPCI2) have been described and many sequence types (ST) of K. pneumoniae have been found to be associated to KPC enzyme production (24) . From a review of the international literature, K.
pneumoniae ST258 clone seems to be the most responsible for KPC dissemination in Europe. This work documents the dissemination of a clonallyrelated KPC-3-positive isolate which belonged to a single clone ST512 strain differing from the national epidemic sequence type (ST) ST258. This result is in agreement with the data reported by other authors in some Italian hospitals (25) proving the spread of two major clones ST258 and ST512.
In conclusion, our work shows that for the initial complete screening it is essential to carry out the Hodge's test as well as the MLB test, AmpC and ESBL; the prompt detection of carbapenemaseproducing strains is critical for the containment of nosocomial transmission. Moreover, the emergence of colistin-resistant K. pneumoniae, given the limited therapeutic options for treatment of these infections, underscores the implementation of active antibiotic resistance surveillance to prevent the spread of this organisms in hospitals.
